XLRN Insider Trading Activity and SEC Form 4 Filings
XLRN insider trading summary
No open-market insider purchases or sales of Acceleron Pharma Inc (XLRN) have been reported on SEC Form 4 in the past 12 months.
Latest XLRN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 27, 2021 | Sujay Kango | EVP, Chief Commercial Officer | Sell | $875K (5,000 @ $175.00) |
| Sep 24, 2021 | Kevin F McLaughlin | SVP, CFO and Treasurer | Sell | $861K (5,370 @ $160.38) |
| Sep 23, 2021 | Kevin F McLaughlin | SVP, CFO and Treasurer | Sell | $159K (983 @ $161.26) |
| Sep 23, 2021 | Kevin F McLaughlin | SVP, CFO and Treasurer | Sell | $3.0M (18,647 @ $160.26) |
| Sep 21, 2021 | Sujay Kango | EVP, Chief Commercial Officer | Sell | $750K (5,000 @ $150.03) |
| Sep 21, 2021 | Adam M Veness | SVP, General Counsel and Sec. | Sell | $998K (6,650 @ $150.05) |
| Sep 9, 2021 | Adam M Veness | SVP, General Counsel and Sec. | Sell | $183K (1,407 @ $130.00) |
| Sep 8, 2021 | Adam M Veness | SVP, General Counsel and Sec. | Sell | $780 (6 @ $130.00) |
| Jul 2, 2021 | Habib J Dable | CEO and President | Sell | $1.5M (11,458 @ $127.51) |
| Jul 2, 2021 | Habib J Dable | CEO and President | Sell | $3.7M (29,140 @ $126.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.